Pages that link to "Q24530647"

The following pages link to Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation (Q24530647):

Displaying 38 items.

• Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A) (Q22010013) (← links)
• Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression (Q22254649) (← links)
• Structure of the GAF domain, a ubiquitous signaling motif and a new class of cyclic GMP receptor (Q24631262) (← links)
• Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A (Q24676441) (← links)
• Conformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF Domain (Q27664639) (← links)
• ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions (Q28145238) (← links)
• Interaction of guanylyl cyclase C with SH3 domain of Src tyrosine kinase. Yet another mechanism for desensitization (Q28185390) (← links)
• Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle (Q28363328) (← links)
• Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts (Q33552229) (← links)
• Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor: (Q33632897) (← links)
• Cyclic nucleotide phosphodiesterases: relating structure and function (Q34047795) (← links)
• PDE4 cAMP-specific phosphodiesterases (Q34364468) (← links)
• Taming platelets with cyclic nucleotides (Q34436565) (← links)
• Phosphodiesterase type 5 (PDE5) inhibitors (Q35140096) (← links)
• Differential expression of PDE5 in failing and nonfailing human myocardium (Q35680934) (← links)
• Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling (Q36324241) (← links)
• Phosphodiesterase 11: a brief review of structure, expression and function (Q36361603) (← links)
• Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells (Q36498599) (← links)
• Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1 (Q36510033) (← links)
• Clinical and molecular genetics of the phosphodiesterases (PDEs). (Q37657841) (← links)
• Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments (Q37947681) (← links)
• Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase (Q38332843) (← links)
• In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation (Q39968459) (← links)
• Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5. (Q41485148) (← links)
• Ectopic expression of bovine type 5 phosphodiesterase confers a renal phenotype in Drosophila. (Q42453932) (← links)
• Regulation of photoreceptor phosphodiesterase catalysis by its non-catalytic cGMP-binding sites (Q42473039) (← links)
• Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. (Q43628509) (← links)
• Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase (Q43826566) (← links)
• Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity (Q44164556) (← links)
• Modeling and mutational analysis of the GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase, PDE5. (Q44371553) (← links)
• Phosphodiesterase type 5 and cancers: progress and challenges (Q47171803) (← links)
• 3',5'-cIMP as Potential Second Messenger in the Vascular Wall (Q51560314) (← links)
• Exploration of signal transduction pathways in cerebellar long-term depression by kinetic simulation. (Q52132207) (← links)
• Studies of the molecular mechanism of discrimination between cGMP and cAMP in the allosteric sites of the cGMP-binding cGMP-specific phosphodiesterase (PDE5) (Q73041166) (← links)
• Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells (Q73118133) (← links)
• Mechanism of transducin activation of frog rod photoreceptor phosphodiesterase. Allosteric interactiona between the inhibitory gamma subunit and the noncatalytic cGMP-binding sites (Q74332760) (← links)
• Chemotherapeutic potential of phosphodiesterase inhibitors (Q77297316) (← links)
• Characterization of the tandem GAF domain of human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme (Q83322995) (← links)